TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
35.07
+0.52 (1.51%)
At close: Nov 22, 2024, 4:00 PM
35.23
+0.16 (0.46%)
After-hours: Nov 22, 2024, 6:59 PM EST
TG Therapeutics Employees
TG Therapeutics had 264 employees as of December 31, 2023. The number of employees increased by 38 or 16.81% compared to the previous year.
Employees
264
Change (1Y)
38
Growth (1Y)
16.81%
Revenue / Employee
$1,002,992
Profits / Employee
-$54,409
Market Cap
5.03B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
ICU Medical | 14,000 |
Integer Holdings | 10,500 |
Haemonetics | 3,657 |
Oscar Health | 2,400 |
Alkermes | 2,100 |
Ultragenyx Pharmaceutical | 1,276 |
BridgeBio Pharma | 556 |
Axsome Therapeutics | 545 |
TGTX News
- 2 days ago - TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ - GlobeNewsWire
- 18 days ago - TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates - Seeking Alpha
- 18 days ago - TG Therapeutics Posts Strong Q3 Briumvi Revenue, Here's Why Shares Fell - Seeking Alpha
- 19 days ago - TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 19 days ago - FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics - GlobeNewsWire
- 22 days ago - TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 2 months ago - TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval - Seeking Alpha
- 2 months ago - New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis - GlobeNewsWire